DEFA14A: Vaxart Pushes Reverse Split to Maintain NASDAQ Listing

Vaxart management strongly urges stockholders to approve a reverse stock split to regain NASDAQ compliance, citing benefits for capital access, visibility, and investor protection.

Summary

• Vaxart is holding a special meeting to discuss and vote on a proposed reverse stock split and a related reduction in authorized shares of common stock.
• The primary goal of the reverse stock split is to regain compliance with NASDAQ's $1 minimum bid price requirement, which is critical for the company's long-term viability.
• NASDAQ listing offers increased visibility, analyst coverage from firms like Jefferies, Oppenheimer, and B. Riley, higher liquidity, and broader access to capital markets with potentially less dilutive terms compared to OTC trading.
• Current trading volume on OTC has decreased from approximately 1.5 million shares per day in 2024 to below 1 million shares per day in 2025, leading to lower liquidity and higher trading costs.
• The reverse stock split is categorized as a 'routine matter' by the New York Stock Exchange for broker voting purposes.
• All insider shares, equity incentive plan shares, and employee stock purchase program shares will be proportionally reduced by the reverse split.
• Preferred shares are not included in the reverse split proposal as they are held in reserve for potential strategic transactions, have no set terms, and NASDAQ rules prevent their use to overcome common share voting.
• The company aims for a post-split stock price range of $5 to $10, which is typical for companies undergoing a reverse split.
• Management believes that reverse splits are common in the biotech industry, and a company's success ultimately depends on scientific inflection points and data.
• A $40 million capital raise in June 2024 was executed concurrently with efforts to secure a BARDA award, aiming to extend the cash runway and fund the norovirus Phase I trial.
• Cost reduction measures included a 10% reduction in full-time employees (FTEs) in Q1 and an additional 21% reduction in Q2, with management stating further cuts would jeopardize essential programs.
• Partnership discussions are ongoing following positive Phase I norovirus data, but these processes involve extensive due diligence and confidentiality, limiting interim updates.
• BARDA contract terms include review privileges that can delay press releases for unanticipated material events.
• The company has not found evidence of illegal dark pool trading or short selling activities impacting its stock price.
• Top-line results for the Phase II COVID trial are anticipated in late 2026, and the norovirus Phase II trial is still months from initiation.
• Vaxart's current cash runway is projected to extend into the first quarter of 2026, indicating a funding gap for ongoing and future programs.
• The avian flu program shows promise, but currently lacks a commercial market, leading the company to explore government partnerships for funding.

Sentiment

Score: 6

Explanation: The company is at a critical juncture, facing NASDAQ delisting if the reverse split isn't approved, which is a significant negative. However, management is transparent about the necessity, highlights pipeline progress (positive norovirus Phase I, BARDA award, COVID KP.2 enrollment), and active pursuit of partnerships and non-dilutive funding. The tone is urgent but also conveys confidence in the science and future potential if the immediate hurdle is cleared. It's not overwhelmingly positive due to the underlying compliance issue, but not entirely negative due to the strategic efforts and scientific progress.

Positives

• Achieved positive Phase I norovirus results, providing important data for future development and partnerships.
• Engaged in constructive partnership discussions following the positive norovirus data, with potential partners conducting due diligence.
• Secured a BARDA project award of $460 million for the COVID Phase IIb trial, demonstrating government interest and support.
• Successfully pivoted the COVID vaccine candidate from XBB to KP.2, showcasing manufacturing agility and responsiveness.
• Maintains strong manufacturing readiness and in-house clinical manufacturing development capabilities in the United States.
• Management and Board members have recently purchased shares, indicating alignment of interests with stockholders.
• Leading independent proxy advisory firms, ISS and Glass Lewis, have recommended that stockholders support the reverse stock split proposal.
• Enrolled approximately 5,000 participants in the KP.2 COVID cohort, which is expected to provide useful information for clinical regulatory development even if the BARDA stop work order is not lifted.

Negatives

• Stockholders previously voted down the reverse stock split proposal, indicating resistance to the measure.
• Trading volume has significantly decreased, from about 1.5 million shares per day in 2024 to below 1 million shares per day in 2025, impacting liquidity.
• Operating on the OTC market results in lower liquidity, larger bid-ask spreads, and higher trading costs for investors.
• Blue Sky laws on the OTC market restrict the company's ability to implement certain fundraising vehicles, such as rights offerings.
• A reverse stock split could lead to increased stock volatility.
• Experienced two stop work orders related to the BARDA agreement, causing program disruptions.
• Current cash runway extends only into Q1 2026, creating a funding gap that needs to be addressed.
• Top-line results for the Phase II COVID trial are not expected until late 2026, and the norovirus Phase II trial is still months from starting, indicating long development timelines.
• There is currently no commercial market for an avian flu vaccine, making funding and advancement challenging.
• The company has not emphasized its platform's differentiation from mRNA vaccines more in public communications despite growing public skepticism towards mRNA.

Risks

• Failure to approve the reverse stock split could lead to delisting from NASDAQ, negatively impacting business viability, visibility, liquidity, and access to capital markets.
• The reverse stock split may result in stock volatility, potentially affecting shareholder value.
• Uncertainty inherent in the clinical development and regulatory approval processes for vaccine candidates.
• Raising capital on the OTC market may involve less favorable terms, such as high discounts and warrant coverage, leading to greater dilution.
• Ongoing stop work orders on the BARDA agreement could further delay or halt the COVID program.
• The limited cash runway into Q1 2026 poses a significant risk if additional funding is not secured in a timely manner.
• Partnership discussions may not materialize or could take longer than anticipated, delaying program advancement and potential non-dilutive funding.
• Competition from other vaccine platforms and companies could impact market share and commercial success.
• Inability to secure non-dilutive funding options, such as government grants, awards, or venture debt, could force reliance on dilutive equity financing.
• The lack of a current commercial market for avian flu vaccine makes its development and funding highly dependent on government initiatives.

Future Outlook

The company's future outlook is critically tied to regaining NASDAQ compliance, which is expected to enhance capital access, institutional investor interest, and overall business viability. Management anticipates important upcoming milestones, including potential partnerships following positive norovirus data and data readouts from the COVID program (sentinel cohort in Q1 2026, full Phase II data late 2026), which are believed to mitigate long-term downside risk. Vaxart is actively pursuing non-dilutive funding options and exploring mechanisms like rights offerings to involve current shareholders in future equity raises.

Management Comments

• "Our goal is to provide clear and direct rationale for this proposal and to address the questions you had about our business and our corporate strategy." Steve Lo
• "Listing on NASDAQ not only helps us advance our science, but it also helps better protect your investment." Steve Lo
• "NASDAQ isn't just better for the company; it's also better for stockholders." Steve Lo
• "Remaining on OTC could negatively impact our business." Steve Lo
• "We understand that a reverse stock split could result in stock volatility. However, we have several important upcoming milestones, including potential partnerships and data readouts. We believe all of these inflection points will mitigate downside risk in the long term." Steve Lo
• "The only plan we presented [to NASDAQ] was going back to our stockholders and asking for approval of the proxy to effect the reverse split." Ed Berg
• "Our goal for us is that, for all NASDAQ companies, is to trade above $1." Steve Lo
• "We've also suffered losses as well, as the management team, for owning the stock." Steve Lo
• "We really need the resources to drive the programs forward and clearly be efficient along the way, but then drive to these key inflection points." Jeroen Grasman
• "These partnerships do take time." Steve Lo
• "We really don't have a hidden agenda here. We want to create stockholder value no matter what stockholder you are." Steve Lo
• "The dream of mine is that we could develop a vaccine that could come to your house rather than having to go wait in line." Sean Tucker
• "Being on NASDAQ helps us compete rather than being at a competitive disadvantage." Sean Tucker

Industry Context

Vaxart operates in the highly competitive biotechnology and vaccine development industry, where reverse stock splits are often a necessary step for companies focused on drug development to reach critical inflection points, distinguishing them from other industries where such actions might signal deeper financial distress. The company is positioning its unique oral vaccine platform as a differentiated alternative to traditional needle vaccines and mRNA technology, particularly in light of increasing public skepticism towards mRNA. Vaxart is also navigating the evolving landscape of vaccine development, transitioning from the rapid, pandemic-driven pace of initiatives like Operation Warp Speed to a more endemic COVID environment, which influences regulatory pathways and market demand. The company is exploring government funding opportunities for programs like avian flu, noting that cancellations of some mRNA approaches might free up capital for novel platforms.

Comparison to Industry Standards

• Vaxart's situation is compared to other biotech companies like Novavax and Dynavax, which also underwent reverse stock splits early in their clinical development and later became billion-dollar companies with commercial sales.
• NASDAQ's stricter corporate governance, financial reporting, and disclosure requirements are highlighted as providing better investor protection compared to the less stringent OTC market, aligning Vaxart with higher industry standards.
• Vaxart's oral vaccine platform is differentiated from mRNA vaccines, with preclinical testing already demonstrating these differences, aiming to offer a potentially safer or more effective alternative.
• The company's manufacturing readiness and in-house capabilities are on par with industry expectations, as demonstrated by its ability to quickly pivot its COVID vaccine candidate from XBB to KP.2 to keep Project NextGen running.

Management Changes

Corporate Governance

Legal Proceedings

• Bob Yedid, a former Board member, pleaded guilty to insider trading, but his activities did not involve his role at Vaxart or trading in Vaxart stock.

Stakeholder Impact

• Shareholders: Directly impacted by the proposed reverse stock split, potential stock volatility, and the need to vote. NASDAQ listing is presented as a measure to protect investment, increase liquidity, and provide better capital access.
• Employees: Affected by significant workforce reductions (10% in Q1, 21% in Q2) as part of cost-cutting measures.
• Potential Partners: Ongoing due diligence and partnership discussions are critical for advancing pipeline programs and securing non-dilutive funding.
• Regulatory Bodies (NASDAQ, SEC): Vaxart is actively working to comply with NASDAQ listing standards, and the SEC oversees the proxy solicitation process.
• Investment Professionals: NASDAQ listing is crucial for attracting institutional investors and maintaining analyst coverage.

Next Steps

• Stockholders are urged to vote on the reverse stock split proposal by 11:59 p.m. Eastern Time on September 4, 2025.
• The Special Meeting of Stockholders to vote on the reverse split will be held on Friday, September 5, 2025, at 8:30 a.m. Pacific Time.
• The company expects to hear back from the NASDAQ Hearings Panel regarding its compliance plan within two to four weeks of the August 14, 2025, hearing.
• Advance the COVID program, with a sentinel cohort readout expected in Q1 2026 and top-line Phase II results in late 2026.
• Advance the norovirus program, with Phase II trials expected to begin in the coming months.
• Continue ongoing partnership discussions for norovirus and other pipeline programs.
• Explore funding avenues for the avian flu program, potentially through government partnerships.
• Aim to submit the avian flu ferret study results for peer-reviewed publication this year.
• Conduct an end of Phase II meeting with the FDA for the COVID program to plan for Phase III advancement.

Key Dates

Recommendation

Vaxart is at a critical juncture where a reverse stock split is necessary to maintain its NASDAQ listing, which is crucial for its long-term viability, access to capital, and institutional investor interest. While the underlying need for a reverse split is a negative signal, management is transparent, has made significant cost reductions, and highlights ongoing scientific progress (positive norovirus Phase I, BARDA award, COVID KP.2 enrollment) and active pursuit of partnerships. The company's cash runway is limited into Q1 2026, creating near-term funding pressure. The stock's future performance heavily depends on the approval of the reverse split, successful execution of clinical trials, and securing partnerships or additional non-dilutive funding. Given the high uncertainty surrounding the vote and the significant funding gap, a 'Hold' recommendation is appropriate for existing investors, awaiting clarity on the reverse split outcome and further progress on key milestones. New investors might consider waiting for these uncertainties to resolve.

Keywords

Vaxart, VXRT, reverse stock split, NASDAQ compliance, oral vaccine, norovirus, COVID-19, avian flu, BARDA, clinical trials, biotechnology, vaccine development, capital raise, corporate governance, stockholder meeting, pharmaceutical